The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that ...

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

Moderna (NASDAQ: MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29 ...

Revenue -- $1.9 billion reported for the quarter, compared to prior sales cycles impacted by earlier U.S. COVID-19 vaccine ...

Fintel reports that on December 12, 2025, Jefferies initiated coverage of Moderna (NasdaqGS:MRNA) with a Hold recommendation. Analyst Price Forecast Suggests 29.18% Upside As of December 5, 2025, the ...

From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 200-day moving average, and this suggests a long ...

According to Benzinga Pro, Moderna Inc's peer group average for short interest as a percentage of float is 6.61%, which means the company has more short interest than most of its peers. Did you know ...

Such warnings are reserved for medications that carry risks of death or life-threatening reactions.

Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a ...